Income Statement
CARIBOU BIOSCIENCES, INC.
CRBU
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
11.16 | 9.99 | 34.48 | 13.85 | 9.60 |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
11.16 | 9.99 | 34.48 | 13.85 | 9.60 |
|
Operating Expenses
|
159.50 | 176.61 | 150.54 | 120.25 | 76.58 |
|
Research & Development
|
109.44 | 130.15 | 112.08 | 82.23 | 52.26 |
|
Selling, General & Administrative
|
37.91 | 46.46 | 38.46 | 38.02 | 24.32 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-148.34 | -166.62 | -116.06 | -106.40 | -66.98 |
|
Non-Operating Income
|
-0.33 | 17.50 | 14.18 | 7.05 | 0.38 |
|
Interest Income
|
- | - | - | - | 0.15 |
|
Interest Expense
|
- | - | - | - | 0.01 |
|
Other Non-Op Income / Expense
|
- | - | - | - | - |
|
Income Before Tax
|
-148.68 | -149.11 | -101.88 | -99.35 | -66.60 |
|
Income Tax Expense
|
-0.55 | -0.01 | 0.19 | 0.07 | 0.32 |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-148.13 | -149.11 | -102.07 | -99.42 | -66.92 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-144.70 | -162.69 | -112.53 | -104.78 | -66.00 |
|
Earnings Per Share (Basic)
|
-1.59 | -1.65 | -1.38 | -1.64 | - |
|
Diluted EPS
|
-1.59 | -1.65 | -1.38 | -1.64 | - |
|
Weighted Average Shares
|
93.39 | 90.32 | 73.81 | 60.80 | - |
|
Diluted Weighted Avg Shares
|
93.39 | 90.32 | 73.81 | 60.80 | - |
|
Comprehensive Income
|
-148.28 | -148.88 | -100.52 | -100.80 | -67.06 |